Clinical Development, Structure Based Drug Design (SBDD) and Targeted Protein Degradation

Molecules of the Month – June 2023

Drug Hunter

JULY 21, 2023

With the popular success of diabetes and weight-loss peptide drugs from Novo (e.g. semaglutide/Ozempic), this month features a pair of ultra-hot non-peptide oral GLP-1R modulators in clinical development.

Structure Based Drug Design (SBDD)

Structure Based Drug Design (SBDD) Targeted Protein Degradation Clinical Trials Trials

Sosei Heptares and Captor Therapeutics Enter Strategic Technology Collaboration Focused on Targeted GPCR Degradation as Novel Approach for Drug Design

The Pharma Data

DECEMBER 21, 2020

Targeted protein degradation (TPD) is an approach whereby the body’s natural process for degrading proteins is diverted using small molecule drugs to eliminate disease-causing proteins. . TOKYO and CAMBRIDGE, England , Dec. No further financial details are disclosed.

Targeted Protein Degradation

Targeted Protein Degradation Small Molecule Structure Based Drug Design (SBDD) Drugs

Sosei Heptares to Explore Structure-based Drug Discovery (SBDD) Approaches to Ion Channels through Strategic Technology Collaboration with Metrion Biosciences

The Pharma Data

JANUARY 31, 2021

This strategic technology collaboration is the latest in a series we have made with highly innovative companies in recent months designed to strengthen our platform and enhance our discovery and partnering opportunities. . TOKYO and CAMBRIDGE, England , Feb.

Structure Based Drug Design (SBDD)

Structure Based Drug Design (SBDD) Targeted Protein Degradation Drugs Disease

Drug Discovery Digest

Molecules of the Month – June 2023

Sosei Heptares and Captor Therapeutics Enter Strategic Technology Collaboration Focused on Targeted GPCR Degradation as Novel Approach for Drug Design

Sosei Heptares to Explore Structure-based Drug Discovery (SBDD) Approaches to Ion Channels through Strategic Technology Collaboration with Metrion Biosciences

Stay Connected